Comparative efficacy and safety between amisulpride and olanzapine in schizophrenia treatment and a cost analysis in China: a systematic review, meta-analysis, and cost-minimization analysis

BACKGROUND: Amisulpride was introduced into China in 2010 as a second-generation atypical antipsychotic, while olanzapine has been on the market since 1999 as one of the leading treatments for schizophrenia in China. Since more Chinese patients are gaining access to amisulpride, the study aims to co...

Descripción completa

Detalles Bibliográficos
Autores principales: Men, Peng, Yi, Zhanmiao, Li, Chaoyun, Qu, Shuli, Xiong, Tengbin, Yu, Xin, Zhai, Suodi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125952/
https://www.ncbi.nlm.nih.gov/pubmed/30185173
http://dx.doi.org/10.1186/s12888-018-1867-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125952/
https://www.ncbi.nlm.nih.gov/pubmed/30185173
http://dx.doi.org/10.1186/s12888-018-1867-8

Ejemplares similares